Phase II study of vinorelbine in patients with hormone refractory prostate cancer

详细信息	查看全文 | 推荐本文 |

• 作者：Caty ; A. ; Oudard ; S. ; Humblet ; Y. ; Beauduin ; M. ; Suc ; E. ; Gil ; Th. ; Rolland ; F. ; Houyau ; Ph. ; Sun ; X. ; et. al.
• 刊名：European Journal of Cancer
• 出版年：1997
• 期刊代码：88_09598049
• 类别：med
• 出版时间：September, 1997
• 卷：33
• 期：Supplement 8
• 页码：S33
• 文件大小：144 K

摘要

Forty seven patients with hormone refractory prostatic cancer (HRPC) were treated with vinorelbine, a hemisynthetic vincaalkaloid. The objectives were to determine time to progression, specific survival, PSA response and toxicities. Entry Criteria: Patients with proven adenocarcinoma of the prostate with metastatic disease clinically progressing after endocrine deprivation based on parameters derived from NPCP criteria. Treatment: Vinorelbine was given at 25 mg/m² weekly for at least 8 weeks or until progression or toxicity.